Targeted therapy targets specific molecules or abnormalities in cancer cells, unlike chemotherapy, which kills all rapidly dividing cells indiscriminately[1][3]. This approach reduces side effects because it spares healthy cells and is better tolerated by patients[1][2][4]. The prerequisite for success is molecular profiling of the tumor to identify mutations and biomarkers[1]. Experts agree that targeted therapies will join chemotherapy as the mainstay of cancer treatment, and combined approaches will improve patient outcomes. For example, belantamab mafodotin in myeloma stops cancer growth for up to three years compared to 13 months with standard drugs[2]. Cetuximab combined with chemotherapy in metastatic colorectal cancer extends progression-free survival from 1.5 to 3.9 months and median survival from 6.9 to 8.6 months[3]. The future lies in combinations of targeted therapies with immunotherapy to overcome resistance[1]. Targeted therapy is indicated for lung, breast, stomach or colon tumors based on genetic testing[4].